{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:33:56Z","timestamp":1793360036145,"version":"4.5.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED) is an autoimmune disorder of the orbit and the most frequent extrathyroidal manifestation of Graves\u2019 disease but it may rarely occur in euthyroid\/hypothyroid patients with chronic autoimmune thyroiditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Epidemiology:<\/jats:title>\n                    <jats:p>TED is a relatively infrequent disorder, particularly in its severe forms. Men tend to have more severe TED at an older age. The prevalence of TED is lower than in the past among patients with recent onset Graves\u2019 hyperthyroidism, and moderate-to-severe forms requiring aggressive treatments are no more than 5% to 6% of all cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Natural history:<\/jats:title>\n                    <jats:p>After an initial inflammatory (active) phase and a plateau phase, TED stabilizes and eventually inactivates (inactive or burnt-out phase) after an estimated period of 18\u201324 months. Minimal-to-mild TED often remits spontaneously, but complete restitutio ad integrum almost never occurs when TED is more than mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Risk factors:<\/jats:title>\n                    <jats:p>Several risk factors contribute to its development on a yet undefined genetic background. Cigarette smoking is the most important of them, but thyroid dysfunction (both hyper- and hypothyroidism), radioactive iodine therapy (if not accompanied by low-dose steroid prophylaxis), elevated thyrotropin receptor antibodies, and, probably, hypercholesterolemia represent relevant modifiable risk factors. Early diagnosis, control and removal of modifiable risk factors, and early treatment of mild forms of GO (local treatment and selenium) may effectively limit the risk of progression to more severe forms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iop.0000000000002467","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:10:53Z","timestamp":1701861053000},"page":"S2-S8","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":67,"title":["Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors"],"prefix":"10.1097","volume":"39","author":[{"given":"Luigi","family":"Bartalena","sequence":"first","affiliation":[{"name":"School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Tanda","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Kahaly","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Johannes Gutenberg University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"R1-20241004","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy.","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"R2-20241004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves\u2019 orbitopathy.","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"R3-20241004","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40618-020-01380-9","article-title":"Thyrotropin receptor antibodies and Graves\u2019 orbitopathy.","volume":"44","author":"Diana","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"R4-20241004","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40618-021-01663-9","article-title":"2021 update on thyroid-associated ophthalmopathy.","volume":"45","author":"Neag","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"R5-20241004","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R6-20241004","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden.","volume":"165","author":"Abraham-Nordling","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R7-20241004","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe Graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt.","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20241004","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center.","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20241004","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/bjophthalmol-2015-306733","article-title":"PREGO (presentation of Graves\u2019 orbitopathy) study: changes in referral patterns to European Group on Graves\u2019 Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.","volume":"99","author":"Perros","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R10-20241004","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement.","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"R11-20241004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves\u2019 orbitopathy (GO) and relationship with thyroid disease.","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R12-20241004","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","article-title":"Graves\u2019 ophthalmopathy: epidemiology and natural history.","volume":"53","author":"Hiromatsu","year":"2014","journal-title":"Intern Med"},{"key":"R13-20241004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/thy.1998.8.423","article-title":"Natural history of thyroid associated ophthalmopathy.","volume":"8","author":"Perros","year":"1998","journal-title":"Thyroid"},{"key":"R14-20241004","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review.","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R15-20241004","article-title":"Presentation of Graves\u2019 orbitopathy within European Group on Graves\u2019 Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).","author":"Schuh","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"R16-20241004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/OPX.0b013e3181ce5702","article-title":"Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases.","volume":"87","author":"Kozaki","year":"2010","journal-title":"Optom Vis Sci"},{"key":"R17-20241004","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","article-title":"Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.","volume":"38","author":"Perros","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R18-20241004","first-page":"473","article-title":"Studies on the occurrence of ophthalmopathy in Graves\u2019 disease.","volume":"120","author":"Marcocci","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"R19-20241004","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1210\/jc.2006-1402","article-title":"Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype.","volume":"91","author":"Manji","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20241004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2265.1992.tb01445.x","article-title":"Graves\u2019 ophthalmopathy in relation to cigarette smoking and ethnic origin.","volume":"36","author":"Tellez","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R21-20241004","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1210\/jc.2015-4294","article-title":"Risk factors for Graves\u2019 orbitopathy; the Australian Thyroid-Associated Orbitopathy (ATOR) study.","volume":"101","author":"Khong","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20241004","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves\u2019 disease.","volume":"133","author":"Stein","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R23-20241004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/eje.0.1480491","article-title":"Multicenter study on the characteristics and treatment strategies of patients with Graves\u2019 orbitopathy: the first European Group on Graves\u2019 Orbitopathy experience.","volume":"148","author":"Prummel","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"R24-20241004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ejim.2008.01.013","article-title":"Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitopathy.","volume":"19","author":"Daumerie","year":"2008","journal-title":"Eur J Intern Med"},{"key":"R25-20241004","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s40618-020-01258-w","article-title":"Asymmetry indicates more severe and active disease in Graves\u2019 orbitopathy: results from a prospective cross-sectional multicentre study.","volume":"43","author":"Perros","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"R26-20241004","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","article-title":"Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy.","volume":"93","author":"Eckstein","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R27-20241004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2415-13-21","article-title":"Unilateral proptosis in thyroid disease with subsequent contralateral involvement: retrospective follow-up study.","volume":"13","author":"Strianese","year":"2013","journal-title":"BMC Ophthalmol"},{"key":"R28-20241004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40618-019-01141-3","article-title":"Orbital diseases mimicking Graves\u2019 orbitopathy: a long-standing challenge in differential diagnosis.","volume":"43","author":"Marin\u00f2","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"R29-20241004","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40618-020-01353-y","article-title":"Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy.","volume":"44","author":"Nicol\u00ec","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"R30-20241004","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1089\/thy.2015.0031","article-title":"Prevalence, phenotype, and psychological well-being in euthyroid\/hypothyroid thyroid-associated orbitopathy.","volume":"25","author":"Ponto","year":"2015","journal-title":"Thyroid"},{"key":"R31-20241004","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1210\/jc.2016-1220","article-title":"Thyroid stimulating antibodies are highly prevalent in Hashimoto\u2019s thyroiditis and associated orbitopathy.","volume":"101","author":"Kahaly","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20241004","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s40618-014-0171-9","article-title":"Graves\u2019-like orbitopathy: do not forget IgG4-related disease.","volume":"37","author":"Bartalena","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"R33-20241004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/thy.1992.2.171","article-title":"Relationship between Graves\u2019 ophthalmopathy and type of treatment of Graves\u2019 hyperthyroidism.","volume":"2","author":"Marcocci","year":"1992","journal-title":"Thyroid"},{"key":"R34-20241004","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","article-title":"Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy.","volume":"150","author":"Prummel","year":"1990","journal-title":"Arch Intern Med"},{"key":"R35-20241004","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/105072502761016476","article-title":"Epidemiology and prevention of Graves\u2019 ophthalmopathy.","volume":"12","author":"Wiersinga","year":"2002","journal-title":"Thyroid"},{"key":"R36-20241004","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy.","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R37-20241004","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association.","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"R38-20241004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy.","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"key":"R39-20241004","first-page":"168","article-title":"Management of Graves\u2019 ophthalmopathy: reality and perspectives.","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"R40-20241004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1442-9071.2004.00756.x","article-title":"Late reactivation of thyroid orbitopathy.","volume":"32","author":"Selva","year":"2004","journal-title":"Clin Experiment Ophthalmol"},{"key":"R41-20241004","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1038\/s41433-020-01297-w","article-title":"Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.","volume":"35","author":"Ugradar","year":"2021","journal-title":"Eye"},{"key":"R42-20241004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/EJE-14-1140","article-title":"Some studies on the natural history of Graves\u2019 orbitopathy: increase in orbital fat is a rather late phenomenon.","volume":"173","author":"Potgieser","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"R43-20241004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","article-title":"Natura history of thyroid associated ophthalmopathy.","volume":"42","author":"Perros","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R44-20241004","first-page":"603","article-title":"Graves\u2019 ophthalmopathy: natural history and treatment outcomes.","volume":"131","author":"Noth","year":"2001","journal-title":"Swiss Med Wkly"},{"key":"R45-20241004","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/thy.2013.0240","article-title":"Spontaneous improvement of untreated mild Graves\u2019 ophthalmopathy: Rundle\u2019s curve revisited.","volume":"24","author":"Menconi","year":"2014","journal-title":"Thyroid"},{"key":"R46-20241004","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12020-016-1136-x","article-title":"Natural history of Graves\u2019 orbitopathy after treatment.","volume":"57","author":"Menconi","year":"2017","journal-title":"Endocrine"},{"key":"R47-20241004","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease.","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"R48-20241004","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40618-014-0214-2","article-title":"Role of genetic and non-genetic factors in the etiology of Graves\u2019 disease.","volume":"38","author":"Marin\u00f2","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"R49-20241004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid.","volume":"79","author":"Wiersinga","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R50-20241004","doi-asserted-by":"crossref","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, Natural history, risk factors, and prevention of Graves\u2019 orbitopathy.","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol"},{"key":"R51-20241004","doi-asserted-by":"crossref","first-page":"725","DOI":"10.20452\/pamw.3592","article-title":"Cigarette smoking: number one enemy for Graves\u2019 ophthalmopathy.","volume":"126","author":"Bartalena","year":"2016","journal-title":"Pol Arch Med Wewn"},{"key":"R52-20241004","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/BF03350047","article-title":"More on smoking habits and Graves\u2019 ophthalmopathy.","volume":"12","author":"Bartalena","year":"1989","journal-title":"J Endocrinol Invest"},{"key":"R53-20241004","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves\u2019 disease.","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"key":"R54-20241004","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","article-title":"Smoking and endocrine ophthalmopathy: impact of smoking severity and current versus lifetime tobacco consumption.","volume":"45","author":"Pfeilschifter","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R55-20241004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","article-title":"Cigarette smoking and treatment outcomes in Graves\u2019 ophthalmopathy.","volume":"129","author":"Bartalena","year":"1998","journal-title":"Ann Intern Med"},{"key":"R56-20241004","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.87.6.773","article-title":"Impact of smoking on the response to treatment of thyroid associated ophthalmopathy.","volume":"73","author":"Eckstein","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R57-20241004","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","article-title":"Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131.","volume":"94","author":"Traisk","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R58-20241004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the management of Graves? Hyperthyroidism.","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"R59-20241004","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves\u2019 hyperthyroidism.","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"key":"R60-20241004","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","article-title":"Use of corticosteroids to prevent progression of Graves\u2019 ophthalmopathy after radioiodine treatment for hyperthyroidism.","volume":"321","author":"Bartalena","year":"1989","journal-title":"N Engl J Med"},{"key":"R61-20241004","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1089\/thy.2019.0150","article-title":"Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves\u2019 disease undergoing radioiodine ablation: a prospective randomized control trial study.","volume":"29","author":"Vannucchi","year":"2019","journal-title":"Thyroid"},{"key":"R62-20241004","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1210\/jc.2005-0507","article-title":"A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves\u2019 ophthalmopathy.","volume":"90","author":"Perros","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R63-20241004","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2009-2130","article-title":"Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves\u2019 orbitopathy: a retrospective cohort study.","volume":"95","author":"Lai","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R64-20241004","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40618-019-01126-2","article-title":"Oral steroid prophylaxis for Graves\u2019 orbitopathy after radioactive iodine treatment for Graves\u2019 disease is not only effective, but also safe.","volume":"43","author":"Rosetti","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"R65-20241004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/biof.5520190308","article-title":"Oxidative stress and Graves\u2019 ophthalmopathy: in vitro studies and therapeutic implications.","volume":"19","author":"Bartalena","year":"2003","journal-title":"Biofactors"},{"key":"R66-20241004","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 ophthalmopathy.","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"R67-20241004","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2009-2470","article-title":"A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves\u2019 orbitopathy.","volume":"95","author":"Lytton","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R68-20241004","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease.","volume":"91","author":"Eckstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R69-20241004","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1089\/thy.1999.9.1175","article-title":"The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves\u2019 disease identifies a group at markedly increased risk of ophthalmopathy.","volume":"9","author":"Khoo","year":"1999","journal-title":"Thyroid"},{"key":"R70-20241004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"R71-20241004","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/thy.2017.0430","article-title":"High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study.","volume":"28","author":"Sabini","year":"2018","journal-title":"Thyroid"},{"key":"R72-20241004","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s40618-018-0915-z","article-title":"Relationship between serum cholesterol and Graves\u2019 orbitopathy (GO): a confirmatory study.","volume":"41","author":"Lanzolla","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"R73-20241004","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1210\/clinem\/dgab070","article-title":"Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves\u2019 disease.","volume":"106","author":"Nilsson","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R74-20241004","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open label, adaptive, single centre randomized clinical trial.","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R75-20241004","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-18-0039","article-title":"Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism.","volume":"178","author":"Wiersinga","year":"2018","journal-title":"Eur J Endocrinol"}],"container-title":["Ophthalmic Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IOP.0000000000002467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T20:09:02Z","timestamp":1728072542000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IOP.0000000000002467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":75,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iop.0000000000002467","relation":{},"ISSN":["0740-9303"],"issn-type":[{"value":"0740-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}